Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
The relationship between plaque pathology and disease duration was examined in 15 patients with multiple sclerosis who died early in the course of their illness. Myelin-stained sections revealed that most plaques examined in patients who died during the first month of their illness showed evidence of ongoing myelin destruction accompanied by a loss of oligodendrocytes. Plaques containing large numbers of oligodendrocytes were not observed in these patients, but were relatively common in patients who died more than 1 month after clinical onset. Remyelination affecting more than 10% of the plaque area was observed in 3 of 82 plaques in 5 patients who died within 10 weeks of clinical onset, in 38 of 105 plaques in 5 patients who died 3 to 10 months after clinical onset, and in 19 of 92 plaques in 5 patients who died 18 months or longer after clinical onset. The study provides new evidence that both oligodendrocytes and myelin are destroyed in new lesions, that this activity ceases completely in many lesions within a few weeks, and that remyelination frequently ensues following repopulation of the plaque by oligodendrocytes. The findings suggest that new lesions normally remyelinate unless interrupted by recurrent activity and that remyelinated shadow plaques are the outcome of a single previous episode of focal demyelination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For cortical grey matter, this now indicates that oligodendrocyte recruitment and remyelination is an early phenomenon in MS lesion formation that occurs in the immediate post-phagocytic phase when foam cells are still abundant in the demyelinated lesions.56-60”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [57]
In the citing paper
“However, despite remyelination being very efficient at the early stages of the disease, this process gradually fails over time [115,116].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [115]
Citations
Cites
Handbook of clinical neurology
(1986) · Journal of Neuroimmunology · doi:10.1016/0165-5728(86)90030-5 · Cited by 1,849
Lantos, P. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.496 · Cited by 1,152
Walton, J. N. (1976) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(76)90157-x · Cited by 964
Payne, J. P. (1969) · British Journal of Anaesthesia · doi:10.1093/bja/41.4.356 · Cited by 600
Remyelination in multiple sclerosis
Prineas, J. W., & Connell, F. (1979) · Annals of Neurology · doi:10.1002/ana.410050105 · Cited by 454
Self-citationRemyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
ULTRASTRUCTURAL STUDY OF REMYELINATION IN AN EXPERIMENTAL LESION IN ADULT CAT SPINAL CORD
Bunge, M. B., Bunge, R. P., & Ris, H. (1961) · The Journal of Cell Biology · doi:10.1083/jcb.10.1.67 · Cited by 396
Proliferating bipotential glial progenitor cells in adult rat optic nerve
ffrench-Constant, C., & Raff, M. C. (1986) · Nature · doi:10.1038/319499a0 · Cited by 385
Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis
Lassmann, H. (1983) · Schriftenreihe Neurologie / Neurology Series · doi:10.1007/978-3-642-45558-2 · Cited by 296
Pathology of the Nervous System
Krigman, M. R. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160150057026 · Cited by 286
Research works printed but not linked: 3
- Schlesinger H, 1909, Zur Frage der akuten multiplen Sklerose und der Enzephalomyelitis disseminata im Kindesalter, Arch Neurol Inst, Wien, 17, 410
- Greenfield JG, 1958, Neuropathology, 441
- Jacob H, 1969, Tissue process in multiple sclerosis and parainfectious and post‐vaccinal encephalomyelitis, Int Arch Allergy Appl Immunol, 36, 22
Cited by
Items 401–500 of 571
Disease Modifying Treatments for Multiple Sclerosis: What is on the Horizon?
Weilbach, F. X., & Gold, R. (1999) · CNS Drugs · doi:10.2165/00023210-199911020-00005 · Cited by 12
Microglia and Multiple Sclerosis
Hammond, B. P., Panda, S. P., Kaushik, D. K., & Plemel, J. R. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_25 · Cited by 11
Perdaens, O., & Pesch, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312637 · Cited by 13
Ishikawa, M., Tsukamoto, T., & Yamamoto, T. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200206 · Cited by 10
0499 Visual evoked potentials in multiple sclerosis patients treated with interferon beta-1a
Liščić, R. M., & Brecelj, J. (2005) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(05)80867-6 · Cited by 11
Promotion of endogeneous remyelination in Multiple Sclerosis
Lucchinetti, C., Noseworthy, J. H., & Rodriguez, M. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300202 · Cited by 14
Jefferson, S., Jacques, T. S., Kiernan, B. W., Scott‐Drew, S., Milner, R., & ffrench‐Constant, C. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300220 · Cited by 14
Therapeutic strategies in multiple sclerosis. II. Long–term repair
Scolding, N. J. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0514 · Cited by 11
Demyelination and Remyelination in Multiple Sclerosis
Bø, L., Esiri, M. M., Evangelou, N., & Kuhlmann, T. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2218-1_2 · Cited by 13
Gudi, V., Schäfer, N., Gingele, S., Stangel, M., & Skripuletz, T. (2021) · Pharmaceuticals · doi:10.3390/ph14111156 · Cited by 13
Kosins, A. M., McConnell, M. P., Mendoza, C., Shepard, B., Scholz, T., Evans, G. R. D., & Keirstead, H. S. (2009) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e3181a65a27 · Cited by 10
Plasminogen activation in multiple sclerosis and other neurological disorders
Akenami, F. O. T., Koskiniemi, M., & Vaheri, A. I. (2000) · Fibrinolysis and Proteolysis · doi:10.1054/fipr.2000.0056 · Cited by 10
Improvement of Peripheral Nerve Regeneration following Immunological Demyelination In Vivo
Kosins, A. M., Scholz, T., Mendoza, C., Lin, P., Shepard, B., Evans, G. R. D., & Keirstead, H. S. (2011) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e31820cf2b0 · Cited by 10
Fillatreau, S., & Anderton, S. M. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.4.565 · Cited by 12
MRI and Proton MRS in the Evaluation of Multiple Sclerosis
Arnold, D. L., Matthews, P. M., & Stefano, N. D. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5863-7_11 · Cited by 11
Filippi, M., & Rocca, M. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-38621-4_1 · Cited by 14
Siponimod supports remyelination in the non-supportive environment
Krüger, J., Behrangi, N., Schliep, D., Heinig, L., Vankriekelsvenne, E., Wigger, N., & Kipp, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-87825-8 · Cited by 11
Siffrin, V. (2025) · Glia · doi:10.1002/glia.70044 · Cited by 11
“Remyelination activity is frequently found alongside active demyelination (Prineas et al. 1993; Raine and Wu 1993) and seems to persist for decades.”
The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?
Ellen, O., Ye, S., Nheu, D., Dass, M., Pagnin, M., Öztürk, E., Theotokis, P., Grigoriadis, N., & Petratos, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311112 · Cited by 14
The future of multiple sclerosis treatment
Cohen, J. A. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70015-2 · Cited by 9
Spring cleaning: time to rethink imaging research lines in MS?
Absinta, M., Reich, D. S., & Filippi, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8060-0 · Cited by 13
Stem Cell and Gene-Based Therapy
Battler, A., & Leor, J. (2006) · Springer eBooks · doi:10.1007/1-84628-142-3 · Cited by 27
Venous Diameter Changes in Chronic Active Multiple Sclerosis Lesions
Weber, C. E., Kraemer, M., Dabringhaus, A., Ebert, A., Platten, M., Gass, A., & Eisele, P. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12818 · Cited by 10
Remyelination of the Central Nervous System
Bruce, C. C., Franklin, R. J. M., & Relvas, J. B. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_19 · Cited by 10
Excitotoxic insults to the optic nerve alter visual evoked potentials
Soto, A., Pérez‐Samartín, A., Etxebarria, E., & Matute, C. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.09.009 · Cited by 9
“…appears to be a major mechanism underlying damage in experimental autoimmune encephalomyelitis (Pitt et al., 2000; Smith et al., 2000), a major model of MS. Remyelination of demyelinated axons is a frequent event in acute and chronic lesions in MS (Prineas et al., 1993; Ozawa et al., 1994).”
BackgroundStem cell transplantation as an approach to brain repair
Armstrong, R. J. E., Jain, M., & Barker, R. A. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.10.1563 · Cited by 9
The clinical application of critical flicker fusion frequency in demyelinating optic neuritis
Fu, J., Wang, Y., Tan, S., Xu, G., Zhou, H., Xu, Q., & Wei, S. (2021) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2021.100011 · Cited by 8
“26 These observations suggest that prompt and effective treatments are necessary to restore myelin integrity during the fi rst 3 months.”
BackgroundKornfeld, S. F., Cummings, S. E., Yaworski, R., Repentigny, Y. D., Gagnon, S., Zandee, S., Fathi, S., Prat, A., & Kothary, R. (2024) · Communications Biology · doi:10.1038/s42003-024-06513-x · Cited by 7
Dericioğlu, V., Turhan, S. A., Erdem, H. E., Sevik, M. O., Erdil, E., Sunter, G., Ağan, K., & Toker, E. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.01.015 · Cited by 10
Recent advances in the neuropathology of multiple sclerosis
Stadelmann, C. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)90475-0 · Cited by 10
Kappa opioid receptor and oligodendrocyte remyelination
Wang, F., & Mei, F. (2019) · Vitamins and hormones · doi:10.1016/bs.vh.2019.05.004 · Cited by 9
Cellular Basis of HIV Infection of the CNS and the AIDS Dementia Complex:
Esiri, M. M., & Morris, C. S. (1995) · Journal of Neuro-AIDS · doi:10.1300/j128v01n01_07 · Cited by 9
Nicolay, D. J., Doucette, J. R., & Nazarali, A. J. (2004) · Glia · doi:10.1002/glia.20028 · Cited by 8
“Remyelination, which is characterized by axons exhibiting thin myelin sheaths, fails with disease progression (Prineas et al., 1989, 1993a,1993b; Raine and Wu, 1993; Brück et al., 1994; Ozawa et al., 1994).”
Autonomic dysfunction in multiple sclerosis and optic neuritis
Saari, A. (2010) · Cited by 8
Skeletal Muscle Adaptations to Disease States
Gea, J., Barreiro, E., & Orozco‐Levi, M. (2007) · Springer eBooks · doi:10.1007/1-4020-5177-8_11 · Cited by 10
Althaus, H. H., Mursch, K., & Klöppner, S. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1053 · Cited by 9
“Demyelinated areas vary in their appearance depending on the type and course of MS (Allen and Kirk, 1997; Brück and Lassmann, 1997; Prineas et al., 1993a).”
BackgroundMultiple Sclerosis Pathology During Early and Late Disease Phases: Pathogenic and Clinical Relevance
Lucchinetti, C. F. (2007) · Springer eBooks · doi:10.1007/978-0-387-36003-4_12 · Cited by 8
Li, J., Durose, W. W., Itô, J., Kakita, A., Iguchi, Y., Katsuno, M., Kunisawa, K., Shimizu, T., & Ikenaka, K. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15190 · Cited by 9
“Remyelination occurs during the early demyelinating disease phases in the border zone of the demyelinating plaque (Jackle et al., 2019; Lassmann, 1983; Prineas et al., 1984, 1993; Prineas, et al., 1993; Schlesinger, 1990; Yeung et al., 2019).”
BackgroundPerdaens, O., Bottemanne, P., & Pesch, V. V. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1336439 · Cited by 8
Towards Personalized Cell-Replacement Therapies for Brain Repair
Lavdas, A. Α., & Matsas, R. (2009) · Personalized Medicine · doi:10.2217/pme.09.4 · Cited by 5
Ciapă, M. A., Donica, V. C., Costea, C. F., & Bogdănici, C. M. (2025) · Diagnostics · doi:10.3390/diagnostics15101189 · Cited by 5
“Recurrent lesions of the demyelinated optic nerve can impair repair processes, leading to permanently demyelinated axons and remyelination failure [32].”
Kosins, A. M., Scholz, T., Lin, M., Evans, G. R. D., & Keirstead, H. S. (2012) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e31823dce7e · Cited by 5
Soustelle, L., Mchinda, S., Hertanu, A., Gherib, S., Pini, L., Guye, M., Ranjeva, J., Varma, G., Alsop, D. C., Pelletier, J., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00235 · Cited by 7
“…myelin destruction have ceased completely, usually within few weeks in many new lesions, the reappearance of oligodendrocytes frequently triggers remyelination, giving rise to remyelin-ated plaques, the so-called shadow plaques ( Lassmann et al., 1997; Patrikios et al., 2006; Prineas et al., 1993).”
BackgroundKelland, E. E., Gilmore, W., Hayardeny, L., Weiner, L. P., & Lund, B. T. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.058 · Cited by 5
Fibroblast Growth Factors in Oligodendrocyte Physiology and Myelin Repair
Decker, L., Lachapelle, F., Magy, L., Picard-Riéra, N., Nait‐Oumesmar, B., & Evercooren, A. B. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_4 · Cited by 5
Genetic Analysis of CNS Remyelination
Bieber, A. J. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-73677-6_7 · Cited by 5
Pathophysiological aspects of the formation of neurological deficit in multiple sclerosis
Переседова, А. В., Baydina, E. V., Trifonova, O., Korepina, O. S., Gnezditskii, V. V., Кротенкова, М. В., Коновалов, Р. Н., Chernikova, L. A., Alekseeva, N. S., Кириченко, И. М., et al. (2008) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-008-9101-7 · Cited by 5
Strategies for achieving and monitoring myelin repair
Rice, C. M., & Scolding, N. J. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0455-x · Cited by 6
A proposal: How to study pro-myelinating proteins in MS
Brod, S. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102924 · Cited by 4
The Study of Remyelinating Therapies in Multiple Sclerosis: Visual Outcomes as a Window Into Repair
Zuroff, L. R., & Green, A. (2024) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002149 · Cited by 4
“22 Remyelination is thought to decrease with age and disease duration, 23,24 suggesting that lifelong exposure to in fl ammation may limit remyelination.”
BackgroundLewis, P. A., & Spillane, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811069-0.00007-0 · Cited by 6
ffrench‐Constant, C., Kiernan, B. W., Milner, R., & Scott‐Drew, S. (1994) · Eye · doi:10.1038/eye.1994.50 · Cited by 4
Frederick, T. J., & Miller, S. D. (2006) · Future Neurology · doi:10.2217/14796708.1.4.489 · Cited by 4
Multiple sclerosis: prospects for remyelination
Raine, C. S. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200405 · Cited by 4
Samanta, J., Silva, H. M., Lafaille, J. J., & Salzer, J. L. (2021) · Scientific Data · doi:10.1038/s41597-021-01063-x · Cited by 6
Lassmann, H., & Vass, K. (1996) · Springer eBooks · doi:10.1007/978-3-642-61191-9_7 · Cited by 4
La sclérose en plaques : quelles possibilités de régénération ?
Lubetzki, C. (2008) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32807-9 · Cited by 4
Neurogenic bladder from multiple sclerosis
Cohen, B. L., Leboeuf, L., & Gousse, A. E. (2008) · Current Bladder Dysfunction Reports · doi:10.1007/s11884-008-0002-y · Cited by 3
Coyle, P. K. (2019) · Current clinical neurology · doi:10.1007/978-3-030-24436-1_3 · Cited by 3
Contributions of the Neocortical Svz to Human Brain Development
Zečević, N., Rakić, S., Jakovčevski, I., & Filipovic, R. (2006) · Springer eBooks · doi:10.1007/0-387-31389-3_4 · Cited by 4
Gass, A., Davie, C. A., Barker, G. J., McDonald, W. I., & Miller, D. (1997) · Der Nervenarzt · doi:10.1007/s001150050229 · Cited by 3
[Nerve growth factor and multiple sclerosis: studies on animal models and in humans].
Aloe, L., Iannitelli, A., & Triaca, V. (2004) · PubMed · Cited by 4
Mechanisms of disability and potential for recovery in multiple sclerosis
Ciccarelli, O., & Toosy, A. (2006) · CRC Press eBooks · doi:10.1201/b14373-2 · Cited by 3
Transplantation myelinbildender Zellen als regenerative Therapie bei Multipler Sklerose
Stangel, M. (2002) · Der Nervenarzt · doi:10.1007/s00115-002-1370-8 · Cited by 3
The New Pathology of Multiple Sclerosis
Lassmann, H. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600609 · Cited by 5
Pathology of the Normal-Appearing White Matter in Multiple Sclerosis
Brück, W., & Stadelmann, C. (2004) · Springer eBooks · doi:10.1007/978-88-470-2127-3_1 · Cited by 4
Protein Kinase C Regulates Process Formation by Oligodendrocytes
Yong, V. W., & Oh, L. Y. S. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5949-8_18 · Cited by 3
Neuroradiologische Aspekte bei Encephalitis disseminata
Reiche, W., Merkelbach, S., & Reith, W. (2000) · Der Radiologe · doi:10.1007/s001170050877 · Cited by 5
Overview of clinical aspects of multiple sclerosis, including cognitive deficit
McDonald, W. I. (1995) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195082937.003.0033 · Cited by 3
van der Knaap, M. S., & Valk, J. (1995) · Springer eBooks · doi:10.1007/978-3-662-03078-3_52 · Cited by 4
Repairing CNS Demyelination by Glial Cell Transplantation
Franklin, R. J. M. (1997) · Springer eBooks · doi:10.1007/978-3-662-03509-2_10 · Cited by 3
Elanghovan, P., Ding, L., Nguyen, T., Zhang, S., Wang, L., Gauthier, D. S. A., & Cho, J. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261418928 · Cited by 2
Targeting of kinases to treat neurodegenerative diseases
Shomali, T., & Trempe, J.-F. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100128 · Cited by 5
“70 Despite advancements in treatment, MS remains a lifelong condition with no cure.”
New advanced therapy medicinal products in treatment of autoimmune diseases
Jahangir, S., Zeydabadinejad, S., Izadi, Z., Habibi‐Anbouhi, M., & Hajizadeh‐Saffar, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00014-1 · Cited by 2
Wilczak, N., Keyser, J. D., & Chesik, D. (2008) · Drug Target Insights · doi:10.4137/dti.s362 · Cited by 2
“Following demyelination, some remyelination of MS lesions can be observed during the early stages of the disease (Prineas et al. 1993), although this is often limited in its extent, and largely fails as the disease progresses.”
BackgroundInfluentialMultiple Sclerosis and Autoimmune Encephalomyelitis
Lassmann, H. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_18 · Cited by 3
Gene and Stem Cell Therapy for Autoimmune Demyelination
Pluchino, S., Bacigaluppi, M., Bucello, S., Butti, E., Deleidi, M., Zanotti, L., Martino, G., & Furlan, R. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_8 · Cited by 2
“In most instances, however, oligodendrocytes or their precursors are morphologically preserved in demyelinating plaques during the early phase of the disease thus remaining capable of differentiation and remyelination (Lucchinetti et al. 1996; Martino and Hartung 1999; Prineas et al. 1993).”
BackgroundNeuroimmunologic Mechanisms in the Etiology of Multiple Sclerosis
Lucchinetti, C. F., Brück, W., & Lassmann, H. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-297-5_19 · Cited by 2
Coyle, P. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-860-7_3 · Cited by 2
Glutamate excitotoxicity in the immunopathogenesis of multiple sclerosis
Werner, P., Brand‐Schieber, E., & Raine, C. S. (2003) · Advances in molecular and cell biology · doi:10.1016/s1569-2558(03)31048-3 · Cited by 2
Pathophysiology of Optic Neuritis
Al‐Louzi, O., & Saidha, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800763-1.00012-9 · Cited by 2
Stem Cell Therapy for Demyelinating Disorders
Pazour, J., & Mokrý, J. (2006) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2017.115 · Cited by 2
Immunologic Aspects of Multiple Sclerosis
Taylor, R. S. (1998) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/s1047-9651(18)30246-8 · Cited by 3
Zhu, F., Huang, H., Shu, Y., Ren, G., Jing, B., Tan, H., Jiang, W., Cui, Y., Worley, P. F., Xiao, B., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07996-0 · Cited by 1
Microglial Function in MS Pathology
Kilpatrick, T. J., & Jokubaitis, V. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2218-1_3 · Cited by 1
Chapter 5 Mechanisms of Symptom Production
Smith, K. J., & McDonald, W. I. (2003) · Blue books of practical neurology · doi:10.1016/s1877-3419(09)70034-0 · Cited by 2
Multiple sclerosis: diagnosis and definitions
Feinstein, A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543760.002 · Cited by 2
The Secret Lives of Human Herpes Virus 6 (HHV-6)
Blumberg, B. M. (2017) · Journal of Neurological Disorders · doi:10.4172/2329-6895.1000352 · Cited by 1
Promotion of remyelination by a thyromimetic drug leading to functional recovery
Duncan, I. D., Vivian, J. A., August, B. K., Keuler, N. S., Komro, A., Radecki, D. Z., Kiland, J. A., Gandhi, R., Reilly, M. J., Cameron, S., et al. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115227 · Cited by 2
Jones, S. (2005) · Elsevier eBooks · doi:10.1016/b978-012738761-1/50017-1 · Cited by 1
Tickle, J. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Birnbaum, G., Leist, T. P., & LUBLIN, F. D. (2007) · Neurology · doi:10.1212/01.wnl.0000275226.67269.a3 · Cited by 1
Cell Transplantation for Diseases of Myelin
Ben‐Hur, T., & Einstein, O. (2006) · Springer eBooks · doi:10.1007/1-84628-142-3_6 · Cited by 1
Perspectives in gene therapy for MS.
Martino, G. (2003) · PubMed · Cited by 2
The adult human oligodendrocyte progenitor
Scolding, N. J. (1997) · Springer eBooks · doi:10.1007/978-3-642-60669-4_25 · Cited by 1
Patterns of demyelination in multiple sclerosis as defined by oligodendrocyte pathology
Brück, W., & Lassmann, H. (1997) · Springer eBooks · doi:10.1007/978-3-642-60669-4_24 · Cited by 1
Cunniffe, N. G. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.77136 · Cited by 3
Multiple sclerosis: a unique immunopathological syndrome of the central nervous system
Hunter, S. F., & Rodriguez, M. (1996) · Springer eBooks · doi:10.1007/978-3-642-61191-9_8 · Cited by 1
Beyer, B. A., Sul, A., Miller, J., Neumann, B., Plaisted, W. C., Kondo, T., Franklin, R. J. M., & Lairson, L. L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.11.548469 · Cited by 1
Molecular Mechanisms of Calcium Influx in Axonal Degeneration
Stys, P. K., & Waxman, S. G. (2005) · Elsevier eBooks · doi:10.1016/b978-012738761-1/50020-1 · Cited by 1
Metadata
- Authors
- Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐.
- Affiliations
- East Orange VA Medical Center (US)
- Rutgers New Jersey Medical School (US)
- Corresponding author
- Prineas, J. W.
- ORCID
- Prineas, J. W.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1993-02
- Volume
- 33
- Issue
- 2
- Pages
- 137-151
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2024751716
- Cited by
- 574
- References
- 46
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 19 · 2018: 14 · 2017: 12 · 2016: 10 · 2015: 14 · 2014: 18 · 2013: 13 · 2012: 16
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, remyelination, demyelination, oligodendrocytes, myelin destruction, disease duration, early-onset multiple sclerosis
- MeSH terms
- Adolescent, Adult, Aged, Axons, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Nerve Regeneration, Oligodendroglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.